Demeetra AgBio, Inc.

PiggyBac: A Simple and Easy to Use Tool to Accelerate Development of Cultured Meats and Cell Lines for the Production of Food Proteins

By Demeetra AgBio, Inc. / May 16, 2022

The food industry has seen a revolution in the last few years with the development of alternative animal-free meat proteins for nutritional purposes. The Boston Consulting Group forecasts this market to reach at least a $290 Billion value by 2035, growing to 11% of total protein consumed. The first wave of development in this nascent…

Read More
Demeetra AgBio

Gene Editing in Plants is Stable, Efficient, and Reliable with Cas-CLOVER, the Clean Alternative to CRISPR/Cas9

By Demeetra AgBio, Inc. / March 22, 2022

Though CRISPR-Cas enabled targeted genome engineering across a vast array of organisms, the system features major disadvantages. Frequent off-target mutagenesis, licensing restrictions and non-ideal economic license terms have inhibited commercial crop-science product upscaling, and, in many cases, entirely disqualified CRISPR’s use by many commercial crop developers. Seeking an alternative to the single-guided Cas9 editing system…

Read More
Demeetra AgBio

Glycoengineering Strategies For Improved Biologics Manufacturing In Mammalian Cells Using Cas-CLOVER

By Demeetra AgBio, Inc. / March 22, 2022

Biologics such as monoclonal antibodies (mABs) and derivatives such as Fc-fusion proteins, antibody-drug conjugates (ADCs), immunocytokines, and antibody-enzyme fusions have ushered in a new era of therapeutics. This new drug class has helped treat cancer, autoimmune disorders and enzyme replacement therapy. Akin to natural proteins (i.e. IgGs), mABs are glycosylated during biosynthesis. IgG glycans consist…

Read More
Demeetra AgBio

ROI Of Using Cas-CLOVER vs. CRISPR/Cas9 In Cell Line Development For Commercial Therapeutic Bioprocessing

By Demeetra AgBio, Inc. / March 21, 2022

Cell line development (CLD), the process of engineering a cell line to manufacture human biologic therapeutics, has harnessed a multitude of technological advancements over the past few years. Traditional methods of gene transfection for biologics production are considered expensive, time-consuming, and riddled with unstable expressions. The CRISPR/Cas9 system completely changed the CLD landscape with targeted…

Read More

Cas-CLOVER Gene Editing Of HEK293 Cells: A Better Investment Than CRISPR For Commercial Gene Therapy And Vaccine Bioprocessing

By Demeetra AgBio, Inc. / March 20, 2022

Viruses equipt with natural abilities as vehicles of gene transfer, promote host-viral co-evolution. For millions of years, the human immune system has been at war with all types of viruses and pathogens, resulting in new serotypes and mechanisms of gene transfer. Humans have complex immune systems and are able to ward off some of them,…

Read More
Demeetra AgBio

Understanding The Commercial Use And Applications Of CRISPR

By Demeetra AgBio, Inc. / March 19, 2022

Many scientific articles make it sound like a simple process to edit a gene of interest, but before CRISPR-based technology, gene editing with other technologies presented major technical challenges. It has made advancements in research far more attainable – in fact, much has already been accomplished with this technology. CRISPR tools and reagents have become…

Read More
Demeetra - Blog - Precise Clonal Selection At Your Fingertips With GS-KO CHO Cells

Precise Clonal Selection At Your Fingertips With GS-KO CHO Cells

By Demeetra AgBio, Inc. / March 18, 2022

As one of the world’s top industries, pharmaceutical companies bring in billions of dollars and save millions of lives. Time and money goes into the process of research and development, drug discovery, and bioprocessing; the necessary parts of getting drugs to market that have potential to save a life. Like with any business, cutting costs…

Read More

Glyco-Engineering Of Yeasts For Biotherapeutics Production Using piggyBac

By Demeetra AgBio, Inc. / March 17, 2022

As many already know, recombinant therapeutic proteins are becoming an integral part of treating an array of conditions from cancer to autoimmune diseases. Almost all of the therapeutic proteins produced today are currently in mammalian cells. However, many other therapeutic protein expression systems exist, such as bacterial, insect, plant, and yeast. Yeasts have multiple advantages…

Read More
Demeetra AgBio

Cas-CLOVER Continues To Show Fewer Off-Target Mutations Than CRISPR/Cas9

By Demeetra AgBio, Inc. / March 16, 2022

Using Unbiased Analysis Cas-CLOVER’s Maximum Potential Off-target Is Under 1% Where CRISPR/Cas9 Is 5-13%. Two off-target analyses have recently been performed with Cas-CLOVER which resemble similar findings in previous research that prove it’s an exceptional alternative to the CRISPR/Cas9 platform. Cas-CLOVER is a cleaner gene editing alternative to CRISPR/Cas9 for research and in particular commercial…

Read More
Demeetra AgBio

CAS-CLOVER: The Clean Alternative to CRISPR/Cas9 For Bioprocessing

By Demeetra AgBio, Inc. / March 15, 2022

Why Cas-CLOVER Is Better Than CRISPR/Cas9 Cas-CLOVER is a cleaner gene editing alternative to CRISPR/Cas9 for commercial bioprocessing similar indel frequencies can be achieved as compared with CRISPR Cas-CLOVER is a highly specific system demonstrating no detectable off-targets Cas-CLOVER (and TAL-CLOVER) are covered by issued patents with clear freedom-to-operate Demeetra is offering evaluation licenses for…

Read More